The HALP score demonstrated high specificity and moderate sensitivity in predicting mortality in AD, suggesting its potential as a complementary biomarker. Its ease of use and accessibility make it suitable for emergency clinical settings. Prospective multicenter studies are needed to confirm its prognostic validity and routine application in AD management.
Şahin et al. (Thu,) studied this question.